Literature DB >> 12675849

Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1-MMP in canine X-linked Alport syndrome (XLAS).

Velidi H Rao1, George E Lees, Clifford E Kashtan, Ryochi Nemori, Rakesh K Singh, Daniel T Meehan, Kathyrn Rodgers, Brian R Berridge, Gautam Bhattacharya, Dominic Cosgrove.   

Abstract

BACKGROUND: Alport syndrome is a group of genetic disorders resulting from mutations in either the alpha3(IV), alpha4(IV) or alpha5(IV) collagen chains. The disease is characterized by a progressive glomerulonephritis, usually associated with a high-frequency specific sensorineural hearing loss, dot and fleck retinopathy, and lens abnormalities. Dogs with naturally occurring genetic disorders of basement membrane collagen (type IV) may serve as animal models of Alport syndrome. In this study, a well-characterized naturally occurring canine model was employed to demonstrate a potential role for matrix metalloproteinases (MMPs) in Alport renal disease pathogenesis.
METHODS: Adolescent male dogs that developed renal failure were euthanized and necropsied. Clinicopathologic features of the disease were characterized, and kidneys from normal and Alport dogs were analyzed by gelatin zymography, Western blotting, in situ zymography, immunohistology, and by reverse transcription polymerase chain reaction (RT-PCR) for expression of MMP-2, MMP-9, and membrane type 1-MMP (MT1-MMP).
RESULTS: Affected dogs developed proteinuria and rapidly progressive juvenile-onset chronic renal failure. The activities of MMP-2 and MMP-9 were significantly induced in Alport kidney. In situ zymography confirmed elevated active metalloproteinases in kidney cryosections of affected dogs. The mRNAs encoding MMP-2, MMP-9 and MT1-MMP were also increased in Alport dogs suggesting that elevated expression of MMPs reflects events in the progression of Alport syndrome in dogs.
CONCLUSION: Elevated expression of MMP-2, MMP-9, and MT1-MMP is observed in fibrotic renal cortex from X-linked Alport syndrome dogs. These findings suggest that MMPs may play an important role in matrix accumulation associated with progressive renal scarring in this model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675849     DOI: 10.1046/j.1523-1755.2003.00939.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

1.  Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells.

Authors:  Maria Alejandra Alfonso-Jaume; Rajeev Mahimkar; David H Lovett
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

2.  Role for macrophage metalloelastase in glomerular basement membrane damage associated with alport syndrome.

Authors:  Velidi H Rao; Daniel T Meehan; Duane Delimont; Motowo Nakajima; Takashi Wada; Michael Ann Gratton; Dominic Cosgrove
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Abnormal basement membrane in the inner ear and the kidney of the Mpv17-/- mouse strain: ultrastructural and immunohistochemical investigations.

Authors:  Angela M Meyer zum Gottesberge; Heidi Felix
Journal:  Histochem Cell Biol       Date:  2005-07-26       Impact factor: 4.304

4.  Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis.

Authors:  Utpal Sen; Charu Munjal; Natia Qipshidze; Oluwasegun Abe; Riyad Gargoum; Suresh C Tyagi
Journal:  Am J Nephrol       Date:  2010-04-16       Impact factor: 3.754

5.  Gene expression analysis in a canine model of X-linked Alport syndrome.

Authors:  Kimberly A Greer; Marnie A Higgins; Melissa L Cox; Timothy P Ryan; Brian R Berridge; Clifford E Kashtan; George E Lees; Keith E Murphy
Journal:  Mamm Genome       Date:  2006-09-08       Impact factor: 2.957

6.  Dysregulation of renal MMP-3 and MMP-7 in canine X-linked Alport syndrome.

Authors:  Velidi H Rao; George E Lees; Clifford E Kashtan; Duane C Delimont; Rakesh Singh; Daniel T Meehan; Gautam Bhattacharya; Brian R Berridge; Dominic Cosgrove
Journal:  Pediatr Nephrol       Date:  2005-03-22       Impact factor: 3.714

Review 7.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

Review 8.  Soluble biglycan as a biomarker of inflammatory renal diseases.

Authors:  Louise Tzung-Harn Hsieh; Madalina-Viviana Nastase; Jinyang Zeng-Brouwers; Renato V Iozzo; Liliana Schaefer
Journal:  Int J Biochem Cell Biol       Date:  2014-08-01       Impact factor: 5.085

9.  Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease.

Authors:  Daniel T Meehan; Duane Delimont; Linda Cheung; Marisa Zallocchi; Steven C Sansom; J David Holzclaw; Velidi Rao; Dominic Cosgrove
Journal:  Kidney Int       Date:  2009-08-26       Impact factor: 10.612

10.  Retinal basement membrane abnormalities and the retinopathy of Alport syndrome.

Authors:  Judy Savige; John Liu; Delia Cabrera DeBuc; James T Handa; Gregory S Hageman; Yan Yan Wang; John D Parkin; Brendan Vote; Rob Fassett; Shirley Sarks; Deb Colville
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.